Format

Send to

Choose Destination
Cancer Cell. 2014 Aug 11;26(2):163-76. doi: 10.1016/j.ccr.2014.05.006. Epub 2014 Jul 17.

Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent.

Author information

1
The Campbell Family Institute for Breast Cancer Research, 101 College Street, Toronto, ON M5G 1L7, Canada.
2
The Campbell Family Institute for Breast Cancer Research, 620 University Avenue, Toronto, ON M5G 2M9, Canada.
3
The Campbell Family Institute for Breast Cancer Research, 620 University Avenue, Toronto, ON M5G 2M9, Canada. Electronic address: tmak@uhnres.utoronto.ca.

Abstract

PLK4 was identified as a promising therapeutic target through a systematic approach that combined RNAi screening with gene expression analysis in human breast cancers and cell lines. A drug discovery program culminated in CFI-400945, a potent and selective PLK4 inhibitor. Cancer cells treated with CFI-400945 exhibit effects consistent with PLK4 kinase inhibition, including dysregulated centriole duplication, mitotic defects, and cell death. Oral administration of CFI-400945 to mice bearing human cancer xenografts results in the significant inhibition of tumor growth at doses that are well tolerated. Increased antitumor activity in vivo was observed in PTEN-deficient compared to PTEN wild-type cancer xenografts. Our findings provide a rationale for the clinical evaluation of CFI-400945 in patients with solid tumors, in particular those deficient in PTEN.

PMID:
25043604
DOI:
10.1016/j.ccr.2014.05.006
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center